An Indispensable Guide to Dry Eye Disease

michael lemp.fwThe Ocular Surface Journal recently published what Dr. Michael Lemp is calling an indispensable guide to a new understanding of Dry Eye Disease. Entitled ‘Rethinking Dry Eye Disease: A Perspective on Clinical Implications’, Lemp adds that the publication’s new conceptual approaches to Dry Eye Disease are more relevant than ever. In this article for The Dry Eye Review, Dr. Lemp summarizes what he believes are some of the key findings within the article.

To read Dr. Michael Lemp’s full article, click here.

Topical Administration of Lacritin is a Novel Therapy for Aqueous-deficient Dry Eye Disease.

Optometry concept

While we continue to search for a new therapeutic drug for our dry eye disease (DED) patients to be approved by the FDA, another potential prospect emerges from a new research endeavor by Vijmasi et al found in Investigative Ophthalmology and Vision … [Continue reading]

Longitudinal Changes in Tear Fluid Lipidome Brought About by Eyelid-warming Treatment in a Cohort of Meibomian Gland Dysfunction

Close-up of a beautiful blond wearing an eye mask

Simple things we can offer our patients many times result in significant benefit. We know meibomian gland dysfunction (MGD) is a leading cause of evaporative dry eye and ocular discomfort characterized by an unstable tear film principally attributed … [Continue reading]

Tracking Tear Osmolarity Numbers from Visit to Visit and the Importance of This Information for Our Patients

cindy matossian.fw

In her fourth article for the Dry Eye Review, Dr. Cynthia Matossian covers the importance of educating and communicating with patients about their dry eye symptoms as well as lifestyle habits during each visit. Matossian also stresses that patient … [Continue reading]

Hyperosmolar Tears Enhance Sensitivity of the Special Corneal Nerves to Ocular Surface Cooling: Possible Neural Basis for Cold-induced Dry Eye Pain

cold air

"Tear hyperosmolarity is a ubiquitous feature of dry eye disease” according to the Aug. 25, 2014 Recently Accepted Papers Alert of Investigative Ophthalmology & Visual Science (IOVS). Harumitsu et al provide extremely interesting evidence in the … [Continue reading]

What Do We Do with the Information We Obtain from Tear Osmolarity Testing

what do we do22.fw

In Dr. Cynthia Matossian's third installment of 'In My Practice', she focuses on the process that occurs after she has obtained a patient's tear osmolarity data. From educating the patient, to treatment recommendations, Dr. Matossian elaborates on … [Continue reading]

Comparative Role of 20% Cord Blood Serum and 20% Autologous Serum in Dry Eye with Hansen’s Disease

Blood from the blood donations in blood laboratory

While we wait for more effective topical ophthalmic pharmaceutical drugs for the treatment of significant dry eye disease (DED) in patients that currently available prescription therapy is insufficient, we should not forget the importance of using … [Continue reading]

Rigel Dry Eye Drug Misses Endpoints in Phase 2


Well, another dry eye disease (DED) drug fails to meet endpoints. Rigel Pharmaceuticals Inc. announced its JAK/SYK inhibitor (R348) did not meet the primary or secondary endpoints in their Phase 2 clinical study. The endpoints were measured by … [Continue reading]

How to Implement Tear Osmolarity Testing in a Practice


It can be difficult to implement any new process into a busy ophthalmology practice. Dr. Cynthia Matossian of Matossian Eye Associates follows up her first feature article by discussing how she approaches introducing a new process into her practice; … [Continue reading]

The Matossian Eye Associates Tear Osmolarity Protocol


In part one of Dr. Cynthia Matossian's four part series, she discusses why and how tear osmolarity is an essential component when determining treatment plans for different types of patients including cataract consults and contact lens wearers. To … [Continue reading]